Filing excerpt
On February 18, 2026, Pravin Desale, Senior Vice President of Research and Development, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense condition of Rule 10b5-1(c), pursuant to which an estimated aggregate of 44,716 shares of our Common Stock may be sold.